Skip to main content
11 May 2025
Last updated:
Saturday 10 May 2025
User account anon menu
Login
Register and subscribe
Search
Home
News
News
Appointments
Events
About MedNous
Who We Are
Editorial Board
Editorial Policy
Research Directory
Research Directory
Organisations
Interviewees
Terms
Topics
Contact Us
Contact Form
Menu
Breadcrumb
Home
Research Directory
Research Directory
FDA guidance on drugs for early Alzheimer's disease
Read more
EMA reflects on 2023
Read more
A regulatory win for a rare disease strategy
Read more
EMA adopts AI workplan
Read more
EMA launches consultation on AI
Read more
FDA draft guidance on psychedelics
Read more
Commentary: FDA guides industry on psychedelic drugs
Read more
US selects first drugs for price negotiations
Read more
The EMA reviews the use of real-world evidence
Read more
Strengths and shortcomings of new EU rules for ATMPs
Read more
Pagination
First page
« First
Previous page
‹‹
Page
1
Current page
2
Page
3
Page
4
Page
5
Page
6
Page
7
Page
8
Page
9
…
Next page
››
Last page
Last »
Home
News
News
Appointments
Events
About MedNous
Who We Are
Editorial Board
Editorial Policy
Research Directory
Research Directory
Organisations
Interviewees
Terms
Topics
Contact Us
Contact Form
